Quetmolimab: A Deep Dive into KANAb 001 and E-6011 The molecule, E-6011, shows a promising approach targeting PD-1. Early clinical data from the two initiatives, KANAb 001 and E-6011, demonstrate encouraging effects in https://www.targetmol.com/compound/quetmolimab